{
    "nctId": "NCT02077933",
    "briefTitle": "Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",
    "officialTitle": "A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients.",
    "overallStatus": "COMPLETED",
    "conditions": "Neoplasms, Breast Neoplasms, Kidney Neoplasms, Pancreatic Neuroendocine Neoplasms (pNETs)",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 79,
    "primaryOutcomeMeasure": "Dose escalation : Incidence of dose Limiting Toxicity (DLTs)",
    "eligibilityCriteria": "Inclusion Criteria For entire trial:\n\n* Adult \\> or = 18 years old\n* has signed the Informed Consent Form\n* has tumor tissue available for the analysis as described in the protocol\n* has an Eastern Cooperative Oncology Group performance status \u22642\n* has adequate bone marrow and organ function as defined in the protocol\n* is able to swallow and retain oral medication\n* has either measurable or non-measurable disease as per RECIST 1.1.\n\nInclusion Criteria for the BYL719+ Everolimus combination - escalation phase - all above plus has a histologically/cytologically confirmed metastatic and/or recurrent solid tumors for whom no standard therapy exists.\n\nInclusion Criteria for the BYL719+ Everolimus combination - expansion phase, renal cell carcinoma cohort - all of above first 7 criteria plus has an histologically/cytologically confirmed Renal Cell Cancer as detailed in the protocol\n\nInclusion Criteria for the BYL719+ Everolimus combination - expansion phase, pancreatic NeuroEndocrine Tumor cohort\n\n- all of above first 7 criteria plus has an histologically/cytologically confirmed pancreatic NeuroEndocrine Tumor as detailed in the protocol\n\nInclusion Criteria for the BYL719+ Everolimus combination - expansion phase, mTOR inhibitor-pretreated patients' cohort - all of above first 7 criteria plus has a histologically and/or cytologically confirmed solid malignancy as described in the protocol\n\nInclusion Criteria for the breast cancer cohorts in escalation and expansion phases, - all of above first 7 criteria plus is post-menopausal and has a histologically and/or cytologically confirmed diagnosis of breast cancer as described in the protocol\n\nSpecific Inclusion Criteria at the time of cross-over (breast cancer, expansion phase),\n\n- Patient randomized to the alpelisib and exemestane combination who has a radiologically documented progressive disease as detailed in the protocol\n\nExclusion Criteria:\n\n* Patient has received previous treatment with a PI3K and/or AKT and/or mTOR inhibitor (mTOR inhibitor is allowed in expansion cohorts where patients should have areceived a prior mTOR inhibitor)\n* Known intolerance or hypersensitivity to Everolimus or other rapamycin analogs\n* Patient with primary central nervous system (CNS) tumor or CNS tumor involvement as detailed in the protocol\n* Patient with diabetes mellitus, or documented steroid-induced diabetes mellitus\n* Patient has a history of another malignancy within 2 years prior to starting study treatment as described in the protocol\n* Patient who has not recovered to grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapy as detailed in the protocol\n* Patient who has had systemic therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to starting study treatment\n* Patient who has received radiotherapy \u2264 4 weeks prior to starting study drugs, with exception of palliative radiotherapy (\u2264 2 weeks prior to starting study drugs), who has not recovered from side effects of such therapy to baseline or Grade \u2264 1 and/or from whom \u2265 30% of the bone marrow was irradiated\n* Patient who has undergone major surgery \u2264 4 weeks prior to starting study treatment or who has not recovered from side effects of such procedure\n* Patient has a clinically significant cardiac disease or impaired cardiac function or any severe and/or uncontrolled medical conditions as detailed in the protocol\n* Patient who is currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatment\n* Patient who has participated in a prior investigational study within 30 days prior to enrollment as described in the protocol\n* Patient who is currently receiving treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzymes CYP34A or CYP2C8 as described in the protocol. Switching to a different medication prior to start of treatment is allowed\n* Patient with impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral alpelisib, everolimus, exemestane\n* Patient with known positive serology for human immunodeficiency virus\n* Patients who have received live attenuated vaccines within 1 week of start of study drug and during the study as specified in the protocol.\n* Pregnant or nursing (lactating) woman as detailed in the protocol.\n* Patient who does not apply highly effective contraception during the study and through the duration as defined in the protocol\n* Patients in the mTOR inhibitor-pretreated cohorts: all of above first 19 criteria plus have discontinued prior mTOR inhibitor therapy due to non-tolerable toxicity",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}